Logo image of BU.CA

BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

TSX:BU - Toronto Stock Exchange - CA1208311029 - Common Stock - Currency: CAD

3.14  +0.45 (+16.73%)

Fundamental Rating

2

Taking everything into account, BU scores 2 out of 10 in our fundamental rating. BU was compared to 29 industry peers in the Chemicals industry. BU has a bad profitability rating. Also its financial health evaluation is rather negative. BU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BU had negative earnings in the past year.
In the past year BU has reported a negative cash flow from operations.
In the past 5 years BU always reported negative net income.
In the past 5 years BU always reported negative operating cash flow.
BU.CA Yearly Net Income VS EBIT VS OCF VS FCFBU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

BU has a worse Return On Assets (-26.96%) than 67.86% of its industry peers.
BU has a Return On Equity of -119.03%. This is in the lower half of the industry: BU underperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -26.96%
ROE -119.03%
ROIC N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
BU.CA Yearly ROA, ROE, ROICBU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BU.CA Yearly Profit, Operating, Gross MarginsBU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BU has more shares outstanding
Compared to 5 years ago, BU has more shares outstanding
Compared to 1 year ago, BU has a worse debt to assets ratio.
BU.CA Yearly Shares OutstandingBU.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
BU.CA Yearly Total Debt VS Total AssetsBU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -6.18, we must say that BU is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.18, BU is doing worse than 71.43% of the companies in the same industry.
A Debt/Equity ratio of 2.80 is on the high side and indicates that BU has dependencies on debt financing.
BU has a Debt to Equity ratio of 2.80. This is in the lower half of the industry: BU underperforms 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Altman-Z -6.18
ROIC/WACCN/A
WACC6.63%
BU.CA Yearly LT Debt VS Equity VS FCFBU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.82 indicates that BU should not have too much problems paying its short term obligations.
BU has a better Current ratio (1.82) than 60.71% of its industry peers.
A Quick Ratio of 1.77 indicates that BU should not have too much problems paying its short term obligations.
BU's Quick ratio of 1.77 is fine compared to the rest of the industry. BU outperforms 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.77
BU.CA Yearly Current Assets VS Current LiabilitesBU.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for BU have decreased strongly by -1323.48% in the last year.
The Revenue has grown by 111.89% in the past year. This is a very strong growth!
Measured over the past years, BU shows a very strong growth in Revenue. The Revenue has been growing by 66.28% on average per year.
EPS 1Y (TTM)-1323.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1578.59%
Revenue 1Y (TTM)111.89%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y143.99%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year723.08%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BU.CA Yearly Revenue VS EstimatesBU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
BU.CA Yearly EPS VS EstimatesBU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BU. In the last year negative earnings were reported.
BU is valuated reasonably with a Price/Forward Earnings ratio of 9.22.
Based on the Price/Forward Earnings ratio, BU is valued cheaper than 92.86% of the companies in the same industry.
BU's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.19.
Industry RankSector Rank
PE N/A
Fwd PE 9.22
BU.CA Price Earnings VS Forward Price EarningsBU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BU.CA Per share dataBU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURCON NUTRASCIENCE CORP

TSX:BU (7/11/2025, 7:00:00 PM)

3.14

+0.45 (+16.73%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)06-25 2025-06-25/amc
Earnings (Next)08-12 2025-08-12
Inst Owners5.92%
Inst Owner ChangeN/A
Ins Owners30.46%
Ins Owner ChangeN/A
Market Cap39.85M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.86%
Min Revenue beat(2)-95.36%
Max Revenue beat(2)-88.35%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1900%
EPS NY rev (3m)1900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.22
P/S 104.47
P/FCF N/A
P/OCF N/A
P/B 5.74
P/tB 7
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)0.34
Fwd EY10.85%
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.03
BVpS0.55
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.96%
ROE -119.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.37%
Cap/Sales 79.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.77
Altman-Z -6.18
F-Score3
WACC6.63%
ROIC/WACCN/A
Cap/Depr(3y)68.17%
Cap/Depr(5y)195.49%
Cap/Sales(3y)82.83%
Cap/Sales(5y)124.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1323.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1578.59%
EPS Next Y143.99%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)111.89%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%N/A
Revenue Next Year723.08%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.44%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.57%
OCF growth 3YN/A
OCF growth 5YN/A